Orgenesis Inc. (ORGS)
OTCMKTS · Delayed Price · Currency is USD
1.180
+0.080 (7.27%)
Nov 18, 2024, 9:30 AM EST

Orgenesis Company Description

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide.

It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.

Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration.

The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services.

The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011.

Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Orgenesis Inc.
Orgenesis logo
Country United States
Founded 2008
Industry Biotechnology
Sector Healthcare
Employees 146
CEO Vered Caplan

Contact Details

Address:
20271 Goldenrod Lane
Germantown, Nevada 20876
United States
Phone 480 659 6404
Website orgenesis.com

Stock Details

Ticker Symbol ORGS
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
ISIN Number US68619K2042
SIC Code 2836

Key Executives

Name Position
Vered Caplan M.Sc. Chairperson of the Board, Chief Executive Officer and President
Prof. Sarah Ferber Ph.D. Founder and Chief Scientific Officer
Victor Miller Chief Financial Officer, Secretary and Treasurer
Pierre Lammeretz Interim Chief Operating Officer
Dr. Shimon Hassin Ph.D. Chief Technology Officer
Joseph Carpinelli Chief Financial Officer of Octomera